Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Fig. 2

Study design. aIn light of the COVID-19 pandemic, the protocol was amended. Patients aiming to enrol in the DESTINATION study who are not able to attend an onsite end of treatment visit in either predecessor study will continue to participate in the 12-week safety follow-up period of either NAVIGATOR (up to week 64) or SOURCE (up to week 60) until on-site randomization and administration of the first dose of study treatment in the DESTINATION study can be conducted. bOnly patients from the NAVIGATOR predecessor study were eligible for a 36-week extended follow-up. EOT end of treatment, LTE long-term extension, Q4W every 4 weeks, R randomization, SC subcutaneously

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us